Clarithromycin use and risk of death in patients with ischemic heart disease.
OBJECTIVE
To examine whether treatment with clarithromycin was associated with an increased risk of death in patients with preexisting ischemic heart disease (IHD).


METHODS
Employing nationwide registers, all patients with IHD events from 1997 to 2007 who subsequently claimed prescriptions for dual antibiotic treatment for eradication treatment were identified. The primary endpoint was all-cause mortality.


RESULTS
The study included 214,330 individuals with IHD; 5,265 (2.5 %) of these claimed prescriptions for dual antibiotics. Compared with IHD patients not undergoing eradication therapy, no increase in the risk of all-cause mortality was demonstrated (HR 1.02; 95% CI 0.84-1.23, p = 0.87) after 5 years.


CONCLUSIONS
The use of clarithromycin in the setting of eradication treatment for Helicobacter pylori in patients with IHD was not associated with an increased risk of death.
Andersen
Søren Skøtt
SS
Department of Cardiology, Gentofte Hospital, Copenhagen, Denmark. ssa@heart.dk
Hansen
Morten Lock
ML
Norgaard
Mette Lykke
ML
Folke
Fredrik
F
Fosbøl
Emil Loldrup
EL
Abildstrøm
Steen Z
SZ
Raunsø
Jakob
J
Madsen
Mette
M
Køber
Lars
L
Gislason
Gunnar H
GH
Torp-Pedersen
Christian
C
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D023521:Chlamydophila Infections / Q000188:drug therapy* / Q000401:mortality*; D016993:Chlamydophila pneumoniae; D017291:Clarithromycin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy / Q000401:mortality; D016480:Helicobacter pylori; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000401:mortality*; D012307:Risk Factors
D000900:Anti-Bacterial Agents; D017291:Clarithromycin